Category - Developments

Developments

Microbix sees record sales in fiscal 2016

Microbix Biosystems (TSX:MBX) expects a strong performance over the rest of the fiscal year based on indicated customer demand, leading the company to project record sales for the current fiscal year, ending Sept. 30...

February 16, 2016

Developments

Avivagen begins trial of OxC-beta with UNAHCO

Avivagen (TSX-V:VIV) has started a trial with UNAHCO at the University of the Philippines Los Banos to measure the benefits of OxC-beta livestock as a feed additive for broiler poultry. Trial design reflects a...

February 11, 2016

Developments

Fresenius extends Endexo accord with Interface Biologics

Fresenius Medical Care (FSE:FME; NYSE:FMS) has extended its exclusive licensing agreement with closely-held Interface Biologics for use of the Endexo technology in chronic dialysis systems to cover the acute dialysis...

February 9, 2016

Developments

Dipexium reaches 75% enrolment in Phase 3 trials

Dipexium Pharmaceuticals’ (NASDAQ:DPRX) OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone in total, with each study having enrolled nearly the same number of patients...

February 4, 2016

Developments

Dipexium Pharma gets Locilex patents in Australia and NZ

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that Australia and New Zealand have issued new Locilex patents, with expiry dates in June 2033. The patents’ claims are directed to a novel formulation of Locilex, an...

February 1, 2016

Developments

Transition Therapeutics reports TT401 trial results

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported results of a Phase 2 clinical study of drug candidate, TT401, for the treatment of Type 2 diabetes. TT401 is a once-weekly administered oxyntomodulin analog...

February 1, 2016

Developments

Knight to sublicense Titan Pharma’s Probuphine in Canada

Titan Pharmaceuticals’ (NASDAQ:TTNP) development and marketing partner, closely-held Braeburn Pharmaceuticals, and Knight Therapeutics (TSX:GUD) have entered into an agreement, giving Knight exclusive rights to...

February 1, 2016

Developments

Venaxis to merge with Strand Life Sciences

Venaxis (NASDAQ:APPY) has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited and its shareholders. Strand is a privately-held, global genomics and bioinformatics company...

January 27, 2016

Developments

Avivagen starts OxC-beta Livestock trial with poultry

Avivagen (TSX-V:VIV) has started a new broiler poultry trial with the institute of agro-food research and technology of Catalonia, Spain. The trial will test the efficacy of OxC-beta Livestock to enhance performance and...

January 27, 2016

Developments

Can-Fite receives patent notice for sexual dysfunction drug

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. The composition of matter...

January 19, 2016

Category - Developments

Subscribe